Combination of lupeol and enzalutamide markedly reduced viability and migration of cancer stem cells and chemoresistant cells (PTEN-CaP8 and PC3), enhanced cell cycle arrest, suppressed mRNA levels of TCF, AR, c-FLIP, and c-MYC, and inhibited tumor growth in murine model. The gene discussed is MYC; the disease is neoplasm.